Pipeline
Pre-Clinical Research Collaborations
Dr. Craig Walsh, UC Irvine, Department of Molecular Biology & Biochemistry
- Immune dysfunction; multisystem senescence: counteracting age-related immune deficiencies by enhancing effector and memory lymphocytes in response to infection/vaccination
Dr. Kim Green, UC Irvine, Department of Neurobiology & Behavior
- Neurogenesis and cognitive decline; neuroinflammation: counteracting age-related neurodegeneration and enhancing hippocampus-dependent cognitive function in aged mouse models
Dr. Athena Soulika, UC Davis, Dept. Dermatology
- Wound healing: ameliorating diabetic ulcers and burn injuries
Pre-Clinical Safety and Efficacy of IMMUNA
Third-party preclinical safety studies confirmed the product to be safe and well tolerated.
Preclinical data supports that IMMUNA benefits vascular function, tissue inflammation, immune cell function, and exosome/extracellular vesicle composition in several age and immune-associated disease indications. Immunis is in the process of publishing preclinical data showing that IMMUNA benefits metabolism.
In published, non-clinical mouse studies in aged mice and in a model of muscle atrophy, IMMUNA was shown to increase muscle mass, increase muscle strength and diminish skeletal muscle fibrosis. These results demonstrate the efficacy of IMMUNA in attenuating loss of muscle mass and muscle fiber area during disuse atrophy in aged mice. We invite you to learn more about these results published in GeroScience.
Pre-clinical studies of our investigational secretome product show a decrease in arterial stiffness with age.